The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
one of these drugs dalceptropip that failed in its clinical trial a detailed genetic study was done post hoc and there were individuals who were found to have a particular genetic variant that looked like on post-hoc analysis that group actually benefited from the drug and that led to a subsequent attempt to do another trial focused specifically on people of that genotype with this CTP inhibitor
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.